Aldosterone synthase inhibitors

US9382226B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Scott B. Hoyt · Hoboken, US
• Min K. Park · Whippany, US
• Clare London · Chatham, US
• Yusheng Xiong · Newtown, US
• D. Jonathan Bennett · Boston, US
• Jiaqiang Cai · Lanark, GB
• Paul Ratcliffe · Lanark, GB
• Andrew Cooke · Doylestown, US
• Emma Carswell · Eaglesham, GB
• John MacLean · Brookline, US
• Rohit Saxena · Sidhauli, IN
• Bheemashankar A. Kulkarni · Noida, IN
• Archana Gupta · Sidhauli, IN

Key dates

• Filing date: Jul 20, 2011
• Grant date: Jul 5, 2016
• Expiry date: Oct 14, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.